(MedPage Today) — The FDA approved milsaperidone (Bysanti) tablets as first-line therapy for adults with schizophrenia and manic or mixed episodes related to bipolar I disorder, Vanda Pharmaceuticals announced on Friday.
Milsaperidone is an active…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
